Radiopharmaceutical firm Clarity Pharmaceuticals has begun recruitment for a phase I/IIA clinical trial evaluating its SARTATE peptide receptor radionuclide therapy for pediatric patients with neuroblastoma.
The open label, dose-escalation trial will administer Cu-67 SARTATE to pediatric patients with high-risk neuroblastoma at Memorial Sloan Kettering Cancer Center in New York.
Neuroblastoma is the most common type of cancer to be diagnosed in children under the age of 1 and accounts for 15% of pediatric cancer deaths. The five-year survival rate for children with high-risk neuroblastoma is only 40%-50%, the researchers noted.
